In a groundbreaking clinical trial, a patient with a rare form of cancer is finding hope through TCR-T Cell Therapy. This innovative immunotherapy approach, conducted through a collaboration between Memorial Cancer Institute and Moffett Cancer Center, involves modifying the patient’s T-cells to target specific proteins in cancer cells. By harnessing the power of the body’s […]
Category: clinical
Tecentriq and lurbinectedin combo improves survival in small cell lung cancer
Exciting news has emerged from the Phase III IMforte study, showcasing the positive impact of combining Roche’s Tecentriq with lurbinectedin for first-line maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC). The data revealed a remarkable 46% reduction in the risk of disease progression or death, along with a 27% decrease in the risk of […]
Fostering Trust in Healthcare Analytics through Responsible Innovation
In the ever-evolving landscape of healthcare analytics, the focus is shifting towards building trust through transparency and responsible innovation. Patients are becoming increasingly conscious of how their data is utilized and are seeking clarity on the automated decision-making processes. The implementation of systems that provide tailored explanations of AI outcomes for different stakeholders, such as […]
Challenges in Gene Therapy for DMD
The year 2024 marked a significant milestone in the field of gene therapy for Duchenne muscular dystrophy (DMD) with the FDA approval of delandistrogene moxeparvovec. This AAV-based gene therapy, developed by Sarepta Therapeutics, delivers a synthetic micro-dystrophin transgene and has shown promise in slowing the progression of the disease. However, despite this progress, challenges remain […]
Advanced Immunotherapy for Aggressive T Cell Cancers
Recent advancements in gene editing have paved the way for a groundbreaking immunotherapy approach that holds promise for treating aggressive T cell cancers. WashU Medicine, a renowned academic institution, is at the forefront of this cutting-edge research. With a substantial research funding portfolio and a commitment to innovation, WashU Medicine is dedicated to pushing the […]
Pharma breakthrough with AbbVie’s ADC in solid tumors
In a significant development, AbbVie’s ADC has showcased its potential to revolutionize solid tumor treatment. Daiichi Sankyo and AstraZeneca are gearing up to unveil phase 3 clinical results for their highly anticipated ADC Enhertu at the upcoming American Society of Clinical Oncology conference. Having already received approval for multiple cancer indications, Enhertu made history as […]
Ascentage Pharma Presents Alrizomadlin Data at ASCO 2025
Ascentage Pharma recently unveiled promising clinical data on the use of Alrizomadlin as a monotherapy and in combination therapies for solid tumors at ASCO 2025. The presentation highlighted the company’s optimistic outlook and strategic plans for future developments in the pharmaceutical industry. Ascentage Pharma’s forward-looking statements, as per the regulations, express the company’s views on […]
Nxera Pharma Receives $15 Million from Neurocrine Biosciences for Phase 3 Trial of NBI-1117568
In a significant development, Nxera Pharma Group has secured a substantial investment of $15 million from Neurocrine Biosciences following the dosing of the first patient in the Phase 3 trial of NBI-1117568. This strategic alliance marks a crucial milestone in the discovery, development, and potential commercialization of innovative pharmaceutical products. However, investors should be aware […]
AAV Gene Therapy Vectors for Hemophilia
Recent research explores the theoretical risk of hepatocellular carcinoma (HCC) following adeno-associated virus (AAV) gene therapy in hemophilia patients. While data from clinical trials are reassuring, concerns remain about long-term oncogenic potential. A single case of HCC post AAV infusion in a patient with prior HCV infection raised questions, but further analysis suggested AAV integration […]
